Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ofri Leitner"'
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-10 (2020)
Abstract Background Hereditary Hemorrhagic Telangiectasia (HHT) is a rare inherited disorder characterized by development of mucocutaneous telangiectases and visceral organ arteriovenous malformations, which can lead to recurrent, spontaneous bleedin
Externí odkaz:
https://doaj.org/article/4645b62ceb4a4cd3815dd99321cb6651
Publikováno v:
Journal of genetic counselingREFERENCES. 31(2)
Genetic testing is an instrumental tool used to determine whether an individual has a predisposition to certain cancers. Knowing of a hereditary cancer predisposition may allow a patient and their family to consider high-risk screening or risk-reduci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eaf74d67f9d9c94c00d7361e13d22c9
https://pubmed.ncbi.nlm.nih.gov/34369024
https://pubmed.ncbi.nlm.nih.gov/34369024
Autor:
Mahin Rehman, Ofri Leitner, Kelly Tangney, Neil Modi, Vivian Chan, April O’Connor, Bhuma Krishnamachari, David Tegay, Sharon Koehler, William Blazey, Jason E. Cohn
Publikováno v:
Journal of cancer education : the official journal of the American Association for Cancer Education. 33(6)
The National Comprehensive Cancer Network (NCCN) guidelines are the gold standard in hereditary cancer risk assessment, screening, and treatment. A minority of physicians follow NCCN guidelines for BRCA1 or BRCA2 mutations. This study assesses the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::844bbe9870e7b58f700e297b0b4864f1
https://pubmed.ncbi.nlm.nih.gov/28573517
https://pubmed.ncbi.nlm.nih.gov/28573517
Autor:
Laura van 't Veer, Lauren Ryan, Taylor Sittler, Ofri Leitner, Sophie B. Adams, Beth Crawford, Salina Chan, Jeroen van den Akker, Elad Gil
Publikováno v:
Breast cancer research and treatment, vol 163, iss 2
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment
Purpose Many women with an elevated risk of hereditary breast and ovarian cancer have previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a subset has hereditary susceptibility to cancer and requires further testing. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738ff5fb7ed050249334f6fb66882aa8
https://escholarship.org/uc/item/04j9x65s
https://escholarship.org/uc/item/04j9x65s
Publikováno v:
Oncology Nursing Forum. 36:E57-E67
PURPOSE/OBJECTIVES To investigate cancer surveillance behaviors of women at risk for hereditary breast and ovarian cancer (HBOC) who presented for clinical BRCA cancer susceptibility testing, specifically to describe cancer surveillance behaviors and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45aa1634c605cc7b4905df00b54e0ce0
https://doi.org/10.1188/09.onf.e57-e67
https://doi.org/10.1188/09.onf.e57-e67
Publikováno v:
Blood. 124:1515-1515
Background: Hereditary Hemorrhagic Telangiectasia (HHT, or Osler Weber Rendu syndrome) is an inherited multiorgan disorder characterized by the development of abnormal blood vessels, resulting in the formation of telangiectasias on mucocutaneous surf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45a80795eb00d9159ff9758b39cb7c92
https://doi.org/10.1182/blood.v124.21.1515.1515
https://doi.org/10.1182/blood.v124.21.1515.1515